According to the US Food and Drug Administration, a decentralized clinical trial (DCT) is one that uses technology to communicate with patient participants remotely and collect clinical data. The studies that fall in line with this definition can take a number of approaches: fully decentralized trials involve patients playing their part entirely from home, and hybrid trials involve a mixture of remote and on-site visits.
There is no one right way to conduct a DCT efficiently and successfully; however, there are some technologies, techniques, and other considerations that can help trial teams get the job done better. Such wisdom is the center of Decentralized Trial Technology, the exclusive Outsourcing-Pharma webinar taking place Wednesday, July 20, at 10 am CST.
Register for this online event and you will hear from a trio of noted industry experts sharing the latest developments in the field, and technologies being put to work in the DCT realm.
Josh Rose, CVS Health Clinical Trial Services
Vice president at CVS Health Clinical Trial Services (CTS), Rose also is a research veteran with more than two decades of experience. In his current role, he leads the CTS clinical trial delivery business providing patient-first research within designated HealthHUB locations, the home, and virtually; he’s also responsible for CTS strategy and partnerships. Prior to joining CVS Health, he was vice president and global head of strategy for the research and development solutions business at IQVIA.
Walter Stadler, University of Chicago Medicine
Celebrated professor of medicine and dean for clinical research, Dr. Stadler is focused on the development of novel therapies and biomarkers in genitourinary cancers and has made notable contributions to the development of gemcitabine in bladder cancer, VEGFR and PD1 checkpoint inhibitors in renal cancer, and various hormonal and other targeted therapies in prostate cancer. He has also explored novel trial designs for growth inhibitory agents, considered the necessary clinical characteristics of both molecular and imaging predictive biomarkers, co-authored consensus statements on prostate cancer clinical trial methodology, and is currently addressing novel pharmacologic approaches to mitigating the cost of care and patient financial toxicity.
Mohammed Ali, Association of Clinical Research Professionals
Ali is a board of Trustee with ACRP, one of the clinical research industry’s most noted professional organizations, as well as chief domain expert with Medable. He has more than two decades of experience with different organizations, and his accomplishments include leading tech transformations and adoption of initiatives to facilitate the scalability of DCTs and digital applications.
The one-hour webinar broadcasts live on July 20 at 10 am CST. In one hour, our presenters will pack in a wealth of knowledge about DCT tools and techniques, and what advances might be on the horizon. Register today, and please feel free to share the sign-up link with colleagues who might benefit from the lively discussion—and if something comes up the day of the event that prevents you from participating live, you can access the event on-demand later.
